Could addressing fibrosis in wet AMD and DME unlock greater durability of treatment? Marion Munk, MD, PhD, joins the show to discuss results from the phase 2a BETTER study, which assessed the use of the anti-fibrosis agent ISTH0036 in patients with wet AMD and DME. And Diana Do, MD, sits down to review data from the LIGHTSITE IIIB study, which examined whether patients who underwent photobiomodulation therapy realized any benefit after re-administration following a 13-month washout period. Did the break in treatment lead to irreversible vision loss? Or were patients able experience a benefit after taking more than a year off? We have the answers in this episode.